vs
Side-by-side financial comparison of Digital Realty (DLR) and Hologic (HOLX). Click either name above to swap in a different company.
Digital Realty is the larger business by last-quarter revenue ($1.6B vs $1.0B, roughly 1.6× Hologic). Hologic runs the higher net margin — 17.1% vs 6.0%, a 11.1% gap on every dollar of revenue. On growth, Digital Realty posted the faster year-over-year revenue change (16.1% vs 2.5%). Over the past eight quarters, Digital Realty's revenue compounded faster (9.8% CAGR vs 1.5%).
Digital Realty is a real estate investment trust that owns, operates and invests in carrier-neutral data centers across the world. The company offers data center, colocation, and interconnection services.
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
DLR vs HOLX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.6B | $1.0B |
| Net Profit | $98.6M | $179.1M |
| Gross Margin | — | 56.0% |
| Operating Margin | 6.9% | 22.6% |
| Net Margin | 6.0% | 17.1% |
| Revenue YoY | 16.1% | 2.5% |
| Net Profit YoY | -10.3% | -10.9% |
| EPS (diluted) | $0.22 | $0.79 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.6B | — | ||
| Q4 25 | $1.6B | $1.0B | ||
| Q3 25 | $1.6B | $1.0B | ||
| Q2 25 | $1.5B | $1.0B | ||
| Q1 25 | $1.4B | $1.0B | ||
| Q4 24 | $1.4B | $1.0B | ||
| Q3 24 | $1.4B | $988.0M | ||
| Q2 24 | $1.4B | $1.0B |
| Q1 26 | $98.6M | — | ||
| Q4 25 | $98.6M | $179.1M | ||
| Q3 25 | $67.8M | $187.2M | ||
| Q2 25 | $1.0B | $194.9M | ||
| Q1 25 | $110.0M | $-17.4M | ||
| Q4 24 | $189.6M | $201.0M | ||
| Q3 24 | $51.2M | $178.6M | ||
| Q2 24 | $80.2M | $194.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | 56.0% | ||
| Q3 25 | — | 55.6% | ||
| Q2 25 | — | 56.3% | ||
| Q1 25 | — | 37.5% | ||
| Q4 24 | — | 56.8% | ||
| Q3 24 | — | 56.4% | ||
| Q2 24 | — | 55.4% |
| Q1 26 | 6.9% | — | ||
| Q4 25 | 6.9% | 22.6% | ||
| Q3 25 | 8.8% | 22.6% | ||
| Q2 25 | 14.2% | 24.9% | ||
| Q1 25 | 13.9% | -0.7% | ||
| Q4 24 | 10.1% | 22.5% | ||
| Q3 24 | 11.8% | 23.3% | ||
| Q2 24 | 0.7% | 24.1% |
| Q1 26 | 6.0% | — | ||
| Q4 25 | 6.0% | 17.1% | ||
| Q3 25 | 4.3% | 17.8% | ||
| Q2 25 | 69.1% | 19.0% | ||
| Q1 25 | 7.8% | -1.7% | ||
| Q4 24 | 13.2% | 19.7% | ||
| Q3 24 | 3.6% | 18.1% | ||
| Q2 24 | 5.9% | 19.2% |
| Q1 26 | $0.22 | — | ||
| Q4 25 | $0.22 | $0.79 | ||
| Q3 25 | $0.15 | $0.84 | ||
| Q2 25 | $2.94 | $0.86 | ||
| Q1 25 | $0.27 | $-0.08 | ||
| Q4 24 | $0.50 | $0.87 | ||
| Q3 24 | $0.09 | $0.75 | ||
| Q2 24 | $0.20 | $0.82 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.5B | $2.4B |
| Total DebtLower is stronger | — | $2.5B |
| Stockholders' EquityBook value | $22.9B | $5.2B |
| Total Assets | $49.4B | $9.2B |
| Debt / EquityLower = less leverage | — | 0.48× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $3.5B | — | ||
| Q4 25 | $3.5B | $2.4B | ||
| Q3 25 | $3.3B | $2.2B | ||
| Q2 25 | $3.6B | $1.9B | ||
| Q1 25 | $2.3B | $1.6B | ||
| Q4 24 | $3.9B | $2.0B | ||
| Q3 24 | $2.2B | $2.3B | ||
| Q2 24 | $2.3B | $2.4B |
| Q1 26 | — | — | ||
| Q4 25 | — | $2.5B | ||
| Q3 25 | — | $2.5B | ||
| Q2 25 | — | $2.5B | ||
| Q1 25 | — | $2.5B | ||
| Q4 24 | — | $2.5B | ||
| Q3 24 | — | $2.5B | ||
| Q2 24 | — | $2.5B |
| Q1 26 | $22.9B | — | ||
| Q4 25 | $22.9B | $5.2B | ||
| Q3 25 | $23.0B | $5.0B | ||
| Q2 25 | $22.9B | $4.8B | ||
| Q1 25 | $21.3B | $4.6B | ||
| Q4 24 | $21.3B | $4.8B | ||
| Q3 24 | $21.2B | $5.1B | ||
| Q2 24 | $20.5B | $5.0B |
| Q1 26 | $49.4B | — | ||
| Q4 25 | $49.4B | $9.2B | ||
| Q3 25 | $48.7B | $9.0B | ||
| Q2 25 | $48.7B | $8.8B | ||
| Q1 25 | $45.1B | $8.5B | ||
| Q4 24 | $45.3B | $8.7B | ||
| Q3 24 | $45.3B | $9.2B | ||
| Q2 24 | $43.6B | $8.9B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.48× | ||
| Q3 25 | — | 0.50× | ||
| Q2 25 | — | 0.52× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | — | 0.53× | ||
| Q3 24 | — | 0.49× | ||
| Q2 24 | — | 0.51× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $229.9M |
| Free Cash FlowOCF − Capex | — | $215.2M |
| FCF MarginFCF / Revenue | — | 20.5% |
| Capex IntensityCapex / Revenue | — | 1.4% |
| Cash ConversionOCF / Net Profit | — | 1.28× |
| TTM Free Cash FlowTrailing 4 quarters | — | $1.0B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $719.0M | $229.9M | ||
| Q3 25 | $652.9M | $355.1M | ||
| Q2 25 | $641.2M | $343.3M | ||
| Q1 25 | $399.1M | $169.4M | ||
| Q4 24 | $769.5M | $189.3M | ||
| Q3 24 | $566.5M | $367.0M | ||
| Q2 24 | $573.2M | $405.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | $215.2M | ||
| Q3 25 | — | $341.4M | ||
| Q2 25 | — | $330.5M | ||
| Q1 25 | — | $153.9M | ||
| Q4 24 | — | $172.5M | ||
| Q3 24 | — | $350.6M | ||
| Q2 24 | — | $385.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | 20.5% | ||
| Q3 25 | — | 32.5% | ||
| Q2 25 | — | 32.3% | ||
| Q1 25 | — | 15.3% | ||
| Q4 24 | — | 16.9% | ||
| Q3 24 | — | 35.5% | ||
| Q2 24 | — | 38.1% |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.4% | ||
| Q3 25 | — | 1.3% | ||
| Q2 25 | — | 1.3% | ||
| Q1 25 | — | 1.5% | ||
| Q4 24 | — | 1.6% | ||
| Q3 24 | — | 1.7% | ||
| Q2 24 | — | 2.0% |
| Q1 26 | — | — | ||
| Q4 25 | 7.29× | 1.28× | ||
| Q3 25 | 9.63× | 1.90× | ||
| Q2 25 | 0.62× | 1.76× | ||
| Q1 25 | 3.63× | — | ||
| Q4 24 | 4.06× | 0.94× | ||
| Q3 24 | 11.07× | 2.05× | ||
| Q2 24 | 7.15× | 2.09× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DLR
Segment breakdown not available.
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
